Advertisement

Advertisement
Breast Cancer

Stage I HER2-Positive Breast Cancer: Long-Term Follow-up of Adjuvant T-DM1

In a 5-year update of the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Tarantino et al found that 1 year of adjuvant ado-trastuzumab emtansine...

Prostate Cancer

Certain Patients Diagnosed With 'Benign' Classification of Prostate Cancer May Actually Have High-Risk Disease

Recently, some experts have called for Gleason Grade Group 1 prostate cancer to be reclassified as benign. However, many patients diagnosed with this lowest grade...

Pancreatic Cancer
Immunotherapy

Resected Pancreatic Cancer: Autologous Dendritic Cell Vaccination

In a Dutch single-center phase I/II study reported in the Journal of Clinical Oncology, van ‘t Land et al found that adjuvant autologous dendritic cell vaccination...


Advertisement
Issues in Oncology

40% of Cancer Cases and Almost Half of All Cancer Deaths in the United States Linked to Modifiable Risk Factors

A recent study led by researchers at the American Cancer Society has found that 4 in 10 cancer cases and about half of all cancer deaths in adults aged 30 and older...

 

Issues in Oncology

Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?

Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1...

Advertisement
Advertisement





More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Capivasertib With Fulvestrant for Previously Treated Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

On November 16, 2023, capivasertib (Truqap) was approved for use with fulvestrant for patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, following disease progression on at least one endocrine-based...

Advertisement

Advanced Classical Hodgkin Lymphoma: PET-Guided BrECADD vs eBEACOPP

As reported in The Lancet by Peter Borchmann, MD, and colleagues, the phase III HD21 trial showed that first-line positron-emission tomography (PET)-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) exhibited greater efficacy and...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Supportive Care
Issues in Oncology

Breaking the Silence: Addressing Sexual and Reproductive Health in Cancer Care

For patients with cancer and cancer survivors, sexual dysfunction and reproductive health concerns are often the elephant in the exam room—a significant quality-of-life issue that both patients and clinicians struggle to discuss openly and effectively. At the recent NCCN Policy Summit on Sexual and ...

Leukemia

Having Acute Lymphoblastic Leukemia Took Away My Fear of Death

On May 30, 2017, 9 days before I turned 19 and soon after I had completed my sophomore year at college, I was diagnosed with aggressive acute lymphoblastic leukemia. But getting to the diagnosis was a tortuous process. I had been feeling fatigued and losing weight for several weeks prior to the...

UK-Based Survey Finds Cancer Is the Leading Health Concern Among the Public

A new survey conducted in the United Kingdom found two-thirds of the public say they are very or somewhat worried about being told they have cancer—a higher percentage than for any other medical condition, including dementia and having a heart attack—according to polling released today. The...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Hematologic Malignancies
Supportive Care

Chronic Graft-vs-Host Disease: Clinical Trial Updates

Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of...

Advertisement

High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem

Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications. Background Melanoma of the skin is the fifth most common cancer type in the...

ASCO Post X Feed
Social Media Hub by Everwall